Argus raised the firm’s price target on Boston Scientific to $80 from $69 and keeps a Buy rating on the shares. As the pandemic has ended and elective procedure volumes have recovered, Boston Scientific has seen strong results in all business segments, and Argus expects the company to continue to benefit from its diverse product portfolio and commitment to innovation, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Piper says competitive process could materialize for ShockWave
- Boston Scientific, Scivita Medical expand strategic cooperation arrangement
- Axonics shareholders approve merger with Boston Scientific
- Boston Scientific price target raised to $77 from $65 at TD Cowen
- Boston Scientific receives FDA approval for Farapulse PFA System